Matching articles for "Cholesterol absorption inhibitors"
Issue 1203 · February 28, 2005 Free
In Brief: Rhabdomyolysis with Ezetimibe

Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):17
Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of ezetimibe ( Zetia in the US; Ezetrol in Canada). Ezetimibe is often added to a statin to increase LDL cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15) . The advisory did not specify whether these patients were also taking a statin, but according to the Canadian manufacturer Merck Frosst/Schering (Merck/Schering-Plough in the US), some of the patients who developed rhabdomyolysis were taking ezetimibe without a statin. In the US, ezetimibe is also available in a combination with simvastatin ( Vytorin - Med Lett Drugs Ther 2004; 46:73) . Recently, a few patients already taking a statin developed myalgia when ezetimibe was added (R Fux et al, Ann Intern Med 2004; 140:671) . The possibility that adding ezetimibe to a statin could increase the risk of rhabdomyolysis should be kept in mind.
Issue 1151 · March 3, 2003
Three New Drugs for Hyperlipidemia

The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol.…

Med Lett Drugs Ther. 2003 Mar 3; 45(1151):17-9
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin ( Mevacor , and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.